Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer
Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer
复制标题
DOI：
10.1001/archinte.160.3.349
复制
发表时间：
2000-02-14
影响因子：
--
通讯作者：
Jick, H
中科院分区：
文献类型：
--
作者：
Meier, CR;Derby, LE;Jick, H
背景：使用血管紧张素转换酶 (ACE) 抑制剂与降低患癌症的风险有关，长期使用钙通道阻滞剂 (CCB) 与患一般癌症，特别是乳腺癌的风险增加有关。 方法：利用全科医学研究数据库的数据，我们进行了一项大型病例对照分析。对 1992 年至 1997 年间被诊断患有乳腺癌的 3706 名绝经后女性和 14155 名匹配对照女性的既往暴露于 ACE 抑制剂、CCB 和 β 受体阻滞剂的情况进行了比较。 结果：与未使用抗高血压药物的女性相比，使用 ACE 抑制剂的女性（比值比 [OR]，1.0；95% 置信区间 [CI]， 0.7-1.5）、CCB（OR，0.9；95% CI，0.7-1.2）或β受体阻滞剂（OR，1.0；95% CI，0.8-1.2）5年或5年以上，患乳腺癌的风险并未增加或降低（根据吸烟和体重指数进行调整[以公斤体重除以米身高平方计算]）。不同ACE抑制剂或不同CCB（二氢吡啶类、盐酸地尔硫卓和盐酸维拉帕米）使用者之间或短效（ORI 1.0；95% CI，0.7-1.4）或缓释（OR，1.0；95% CI，0.8-1.3）硝苯地平制剂使用者之间，乳腺癌风险没有差异。结论：本研究的结果大型病例对照分析并不支持长期使用 ACE 抑制剂或 CCB 会影响患乳腺癌风险的假设。
Background: The use of angiotensin-converting enzyme (ACE) inhibitors has been linked to a decreased risk of developing cancer, and longer-term use of calcium channel blockers (CCBs) has been associated with an increased risk of developing cancer in general and breast cancer in particular.Methods: Using data from the General Practice Research Database, we conducted a large case-control analysis. Previous exposure to ACE inhibitors, CCBs, and beta-blockers was compared between 3706 postmenopausal women who were diagnosed with incident breast cancer between 1992 and 1997 and 14 155 matched-control women.Results: Compared with nonusers of antihypertensive drugs, women who used ACE inhibitors (odds ratio [OR], 1.0; 95% confidence interval [CI], 0.7-1.5), CCBs (OR, 0.9; 95% CI, 0.7-1.2), or beta-blockers (OR, 1.0; 95% CI, 0.8-1.2) for 5 or more years were not at an increased or decreased risk of developing breast cancer (adjusted for smoking and body mass index [calculated as weight in kilograms divided by the square of height in meters]). The risk of breast cancer did not differ between users of different ACE inhibitors or different CCBs (dihydropyridines, diltiazem hydrochloride, and verapamil hydrochloride) or between users of short-acting (ORI 1.0; 95% CI, 0.7-1.4) or sustained-release (OR, 1.0; 95% CI, 0.8-1.3) nifedipine preparations.Conclusion: The findings of this large case-control analysis do not support the hypothesis that longer-term use of ACE inhibitors or CCBs affects the risk of developing breast cancer.